ozarelix, developmental, code, names, 63153, peptide, gonadotropin, releasing, hormone, antagonist, gnrh, antagonist, which, under, development, aeterna, zentaris, spectrum, pharmaceuticals, long, acting, injection, formulation, treatment, prostate, cancer, al. Ozarelix developmental code names D 63153 SPI 153 is a peptide gonadotropin releasing hormone antagonist GnRH antagonist which is or was under development by AEterna Zentaris Inc and Spectrum Pharmaceuticals as a long acting injection formulation for the treatment of prostate cancer 1 2 It has also been investigated for the treatment of endometriosis but no development has been reported 1 The drug was previously under investigation for the treatment of benign prostatic hyperplasia and Alzheimer s disease as well but development for these indications was discontinued 1 As of June 2015 it was in phase II clinical trials for prostate cancer 1 It seems to no longer be under development 1 OzarelixClinical dataOther namesD 63153 SPI 153Routes ofadministrationInjectionDrug classGnRH modulator GnRH antagonist AntigonadotropinIdentifiersIUPAC name 2S 1 2S 2 2S 2 2R 2 2S 2 2S 2 2R 2 2R 2 2R 2 Acetamido 3 naphthalen 2 ylpropanoyl amino 3 4 chlorophenyl propanoyl amino 3 pyridin 3 ylpropanoyl amino 3 hydroxypropanoyl methylamino 3 4 hydroxyphenyl propanoyl amino 6 carbamoylamino hexanoyl amino hexanoyl amino 5 diaminomethylideneamino pentanoyl N 2R 1 amino 1 oxopropan 2 yl pyrrolidine 2 carboxamideCAS Number295350 45 7 896710 46 6 acetate PubChem CID25080293DrugBankDB12581ChemSpider17291594UNIIQ1IF8M2YL3CompTox Dashboard EPA DTXSID60183722ECHA InfoCard100 232 650Chemical and physical dataFormulaC 72H 96Cl N 17O 14Molar mass1459 12 g mol 13D model JSmol Interactive imageSMILES CCCC C H C O N C H CCCN C N N C O N1CCC C H 1C O N C H C C O N NC O C H CCCCNC O N NC O C H CC2 CC C C C2 O N C C O C H CO NC O C H CC3 CN CC C3 NC O C H CC4 CC C C C4 Cl NC O C H CC5 CC6 CC CC C6C C5 NC O CInChI InChI 1S C72H96ClN17O14 c1 5 6 17 52 63 96 85 54 19 12 33 79 71 75 76 70 103 90 34 13 20 59 90 67 100 81 42 2 61 74 94 83 62 95 53 18 9 10 32 80 72 77 104 84 68 101 60 39 45 24 29 51 93 30 25 45 89 4 69 102 58 41 91 88 66 99 57 38 47 14 11 31 78 40 47 87 65 98 56 36 44 22 27 50 73 28 23 44 86 64 97 55 82 43 3 92 37 46 21 26 48 15 7 8 16 49 48 35 46 h7 8 11 14 16 21 31 35 40 42 52 60 91 93H 5 6 9 10 12 13 17 20 32 34 36 39 41H2 1 4H3 H2 74 94 H 81 100 H 82 92 H 83 95 H 84 101 H 85 96 H 86 97 H 87 98 H 88 99 H4 75 76 79 H3 77 80 104 t42 52 53 54 55 56 57 58 59 60 m1 s1Key KATZUZNTRINHDT HALMFYTRSA NSee also editGonadotropin releasing hormone receptor AntagonistsReferences edit a b c d e Ozarelix AdisInsight Festuccia C Dondi D Piccolella M Locatelli A Gravina GL Tombolini V Motta M 2010 Ozarelix a fourth generation GnRH antagonist induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors Prostate 70 12 1340 9 doi 10 1002 pros 21169 PMID 20623634 S2CID 2788093 External links editOzarelix AdisInsight nbsp This drug article relating to the genito urinary system is a stub You can help Wikipedia by expanding it vte nbsp This hormonal preparation article is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Ozarelix amp oldid 1187432479, wikipedia, wiki, book, books, library,
